INDBInternet News Database 2.5 Updated just now · 297 sources Show or hide images Light or dark

Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026

1 source1 article First seen Updated United States Truth score 34

Save Like Comments Compare coverage
Image from Amherst Bee

Summary

Updated longer-term analysis, including up to four years of follow-up data in patients with relapsed or refractory BRAF-altered pediatric low-grade glioma treated with OJEMDA®(tovorafenib), will be presented as an oral presentation on November 14 at 3:45 p.m. ESTData expand on…

Description from Amherst Bee.

Who is covering this

  1. Amherst Bee Not rated US
    Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026

    Updated longer-term analysis, including up to four years of follow-up data in patients with relapsed or refractory BRAF-altered pediatric low-grade glioma treated with OJEMDA®(tovorafenib), will be presented as an oral presentation on November 14 at 3:45 p.m. ESTData expand on…

Comments

Comments need JavaScript.